BICO Group AB (OTCPK:CLLKF)

Q3 2025 BICO Group AB Earnings Call Transcript

Nov 4, 2025 / 09:00 AM GMT

Release Date Price: $2.56

Transcript

Key Points

Positve

BICO Group AB (CLLKF) reported a 12% organic sales growth in Q3 2025, despite macroeconomic challenges.
The Life Science Solutions segment delivered 4% organic sales growth, driven by increased demand for diagnostics and lab automation components.
Lab Automation segment rebounded with a 35% organic sales growth, showcasing strong demand for automation solutions.
The company secured a significant $15.2 million order from a global pharma company, highlighting strong demand for its lab automation solutions.
BICO Group AB (CLLKF) strengthened its cash position by generating 740 million from divestments, enhancing financial stability.

Negative

The company faced impairments totaling 1 billion 36 million, impacting EBIT for the quarter.
Academic and biotech funding remains constrained, particularly in North America, leading to cautious customer spending.
The company experienced a negative cash flow from operating activities amounting to negative 32 million, impacted by working capital changes.
There are ongoing challenges with extended sales cycles due to constrained funding in key markets.
Despite improvements, the profitability of the Lab Automation segment is still impacted by substantial investments in operational resources.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BICO.ST - BICO Group AB
Q3 2025 BICO Group AB Earnings Call
Nov 04, 2025 / 09:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to BICO Group's Quarter 3 2025 earnings call. I'm Maria Force, President and CEO, and I will, together with BICO CFO Jakob Thornberg, present this interim report.

Here's today's agenda. I will open today's session by presenting how BIO serves the world's leading pharma and biotech companies with solutions that transform how labs operate and innovate.

Following that, Jakob will provide a summary of the quartet's key developments and present the group's financial performance.

We'll proceed and comment on our two business areas, life science solutions and lab automation.

Additionally, we will highlight our R&D pipeline with ongoing project development efforts, and the session will conclude

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.